Insulin resistance modifies the association between obesity and current asthma in adults

Juan Carlos Cardet, Samuel Ash, Tope Kusa, Carlos A Camargo Jr, Elliot Israel, Juan Carlos Cardet, Samuel Ash, Tope Kusa, Carlos A Camargo Jr, Elliot Israel

Abstract

Insulin resistance potentiates the association between obesity and childhood asthma, but this relationship appears inconsistent in relatively small studies of adults. We investigated effect modification in adults using the National Health and Nutrition Examination Survey 2003-2012, a large, nationally representative database.Insulin resistance and a history of physician-diagnosed current asthma were obtained from 12 421 adults, ages 18-85 years. We used logistic regression to determine associations between obesity and current asthma, adjusting for age, sex, race/ethnicity, poverty income ratio and smoking status. An interaction term evaluated effect modification by insulin resistance of the obesity-asthma association.As expected, obesity was positively associated with current asthma. Insulin resistance modified this association, with obesity measured as body mass index, waist circumference or waist-to-height ratio. The relationship between obesity and current asthma was stronger with increasing insulin resistance tertiles (OR 2.05, 95% CI 2.76-3.00; p-value for interaction 0.03). This association was robust to adjustments for other components of the metabolic syndrome (hypertriglyceridaemia, hypertension, hyperglycaemia and systemic inflammation). None of these components were themselves effect modifiers of the obesity-asthma association.In this large, nationally representative sample, insulin resistance modified the association between obesity and current asthma in adults. Targeting insulin resistance may represent a novel therapeutic strategy for obese patients with asthma.

Conflict of interest statement

Conflict of interest: None declared.

Copyright ©ERS 2016.

Figures

FIGURE 1
FIGURE 1
Relationship between between body mass index (BMI) and current asthma stratified by tertiles of insulin resistance. The BMI categories were lean (−2), overweight (≥25 and <30 kg·m−2) and obese (≥30 kg·m−2). p-value for interaction 0.03.

References

    1. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–814.
    1. Moorman JE, Zahran H, Truman BI, et al. Current asthma prevalence – United States, 2006–2008. MMWR Surveill Summ. 2011;60(Suppl):84–86.
    1. Moorman JE, Person CJ, Zahran HS. Asthma attacks among persons with current asthma – United States, 2001–2010. MMWR Surveill Summ. 2013;62(Suppl 3):93–98.
    1. Gibeon D, Batuwita K, Osmond M, et al. Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI. Chest. 2013;143:406–414.
    1. Sutherland ER, Goleva E, King TS, et al. Cluster analysis of obesity and asthma phenotypes. PLoS One. 2012;7:e36631.
    1. Telenga ED, Tideman SW, Kerstjens HA, et al. Obesity in asthma: more neutrophilic inflammation as a possible explanation for a reduced treatment response. Allergy. 2012;67:1060–1068.
    1. Sutherland ER, Goleva E, Strand M, et al. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med. 2008;178:682–687.
    1. Rodrigo GJ, Plaza V. Body mass index and response to emergency department treatment in adults with severe asthma exacerbations: a prospective cohort study. Chest. 2007;132:1513–1519.
    1. Peters-Golden M, Swern A, Bird SS, et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006;27:495–503.
    1. Camargo CA, Jr, Boulet LP, Sutherland ER, et al. Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast. J Asthma. 2010;47:76–82.
    1. Boulet LP, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med. 2007;101:2240–2247.
    1. Sideleva O, Suratt BT, Black KE, et al. Obesity and asthma: an inflammatory disease of adipose tissue not the airway. Am J Respir Crit Care Med. 2012;186:598–605.
    1. McLachlan CR, Poulton R, Car G, et al. Adiposity, asthma, and airway inflammation. J Allergy Clin Immunol. 2007;119:634–639.
    1. Al-Alwan A, Bates JH, Chapman D, et al. The non-allergic asthma of obesity: a matter of distal lung compliance. Am J Respir Crit Care Med. 2014;189:1494–1502.
    1. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181:315–323.
    1. Field AE, Camargo CA, Jr, Ogino S. The merits of subtyping obesity: one size does not fit all. JAMA. 2013;310:2147–2148.
    1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645.
    1. Brumpton BM, Camargo CA, Jr, Romundstad PR, et al. Metabolic syndrome and incidence of asthma in adults: the HUNT study. Eur Respir J. 2013;42:1495–1502.
    1. Al-Shawwa B, Al-Huniti N, Titus G, et al. Hypercholesterolemia is a potential risk factor for asthma. J Asthma. 2006;43:231–233.
    1. Forno E, Han YY, Muzumdar RH, et al. Insulin resistance, metabolic syndrome, and lung function in US adolescents with and without asthma. J Allergy Clin Immunol. 2015;136:304–311.
    1. Baffi CW, Wood L, Winnica D, et al. Metabolic syndrome and the lung. Chest. 2016;149:1525–1534.
    1. Ma J, Xiao L, Knowles SB. Obesity, insulin resistance and the prevalence of atopy and asthma in US adults. Allergy. 2010;65:1455–1463.
    1. Thuesen BH, Husemoen LL, Hersoug LG, et al. Insulin resistance as a predictor of incident asthma-like symptoms in adults. Clin Exp Allergy. 2009;39:700–707.
    1. National Health and Nutrition Examination Survey. About the National Health and Nutrition Examination Survey. [Date last accessed: July 21, 2015]; Date last updated: February 3, 2014.
    1. National Health and Nutrition Examination Survey. About the National Health and Nutrition Examination Survey. Questionnaires, Datasets, and Related Documentation. [Date last accessed: July 21, 2015]; Date last updated: October 30, 2015.
    1. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179–187.
    1. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–338.
    1. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–1495.
    1. Konner AC, Bruning JC. Selective insulin and leptin resistance in metabolic disorders. Cell Metab. 2012;16:144–152.
    1. Otero YF, Stafford JM, McGuinness OP. Pathway-selective insulin resistance and metabolic disease: the importance of nutrient flux. J Biol Chem. 2014;289:20462–20469.
    1. Agrawal A, Mabalirajan U, Ahmad T, et al. Emerging interface between metabolic syndrome and asthma. Am J Respir Cell Mol Biol. 2011;44:270–275.
    1. Biddinger SB, Kahn CR. From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol. 2006;68:123–158.
    1. Lessmann E, Grochowy G, Weingarten L, et al. Insulin and insulin-like growth factor-1 promote mast cell survival via activation of the phosphatidylinositol-3-kinase pathway. Exp Hematol. 2006;34:1532–1541.
    1. Dupont J, Khan J, Qu BH, et al. Insulin and IGF-1 induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis. Endocrinology. 2001;142:4969–4975.
    1. Terzano C, Morano S, Ceccarelli D, et al. Effect of insulin on airway responsiveness in patients with type 2 diabetes mellitus: a cohort study. J Asthma. 2009;46:703–707.
    1. Derosa G, Maffioli P, Salvadeo SA, et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60’s study. Metabolism. 2009;58:1059–1066.
    1. Darwish KM, Salama I, Mostafa S, et al. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists. Eur J Med Chem. 2016;109:157–172.
    1. Literati-Nagy B, Kulcsar E, Literati-Nagy Z, et al. Improvement of insulin sensitivity by a novel drug, BGP-15, in insulin-resistant patients: a proof of concept randomized double-blind clinical trial. Horm Metab Res. 2009;41:374–380.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere